This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
by Zacks Equity Research
Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.
Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
by Zacks Equity Research
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.
Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?
by Zacks Equity Research
With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Top and Flop ETFs of January 2018
by Sanghamitra Saha
Inside the best and worst-performing ETFs of January.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.
Company News For Jan 30, 2018
by Zacks Equity Research
Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO
Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B
by Zacks Equity Research
Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
This biotech ETF hit a new 52-week high. Are more gains in store for this fund?
Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ
by Swarup Gupta
The government shutdown in the United States guided stocks across Europe and Asia last week.
Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat
by Zacks Equity Research
Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.
Play Biotech Buyout Frenzy With These 2 Solid Funds
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas
Stock Market News For Jan 23, 2018
by Zacks Equity Research
Major benchmarks hit record highs on Monday after the Senate gave its consent to pass a Bill that ends the current government shutdown.
Regeneron's Dupixent Receives MHLW Nod for Label Expansion
by Zacks Equity Research
Ministry of Health, Labor and Welfare (MHLW) in Japan has granted approval for the label expansion of Regeneron's (REGN) Dupixent.
Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks
by Tirthankar Chakraborty
More deals are expected to be signed in the biotech space, now that the tax reform bill allows companies to repatriate cash pilling up overseas.
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?
by Arpita Dutt
Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?
Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips
by Zacks Equity Research
Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?
by Arpita Dutt
Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.
CES 2018 Promises a Thrilling Year for Gaming Enthusiasts
by Zacks Equity Research
During CES 2018, a number of companies displayed some extravagant products which are set to change the gaming experience entirely this year.
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
by Arpita Dutt
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
Emergent Down on '18 View, Posts Preliminary '17 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2017 and its guidance for 2018. The results exceed management's outlook issued in November last year.
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation
by Zacks Equity Research
AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
by Zacks Equity Research
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.